Italian CRO standardizes on Vault eTMF and Vault CTMS to improve
trial efficiency and enhance collaboration with sponsors
VIENNA--(BUSINESS WIRE)--
DIA Europe 2019 -- Veeva
Systems (NYSE:VEEV) today announced that Clinical Organization for
Strategies & Solutions (CLIOSS) implemented Veeva
Vault eTMF and Veeva
Vault CTMS to give sponsors better visibility into trial activities.
With Veeva Vault clinical applications, CLIOSS is unifying its clinical
systems and streamlining trial processes on a single platform to improve
trial performance.
“We needed a modern system that could manage our increasingly complex
trial activities,” said Cristina Davite, managing director at CLIOSS.
“Veeva Vault allows us to work more efficiently with sponsors and
deliver high-quality studies more quickly. Now we have a clinical
solution that will help us succeed on a global scale.”
CLIOSS, a NMS Group company, is expanding to the fast-growing Chinese
clinical research market through a recent merger. The contract research
organization (CRO) wanted to move away from manual, paper-based
processes to improve how it collaborates with sponsors in China and
Europe.
Vault eTMF enables an active TMF operating model where all processes and
documents are managed in one system, in real-time, as they are executed
to maintain a constant state of inspection-readiness. With Vault CTMS,
study teams and partners gain greater insights across the trial
lifecycle for improved decision-making and study quality.
Together, Veeva Vault applications make it easy to share documents in
real-time. For example, when CLIOSS team members create site monitoring
visit reports in Vault CTMS, those reports are automatically available
in Vault eTMF. This reduces manual data entry and improves information
sharing with cross-functional teams and sponsors.
“CROs are leading a major industrywide shift to unify clinical
operations for improved study execution,” said Rik Van Mol, vice
president of development cloud strategy, Europe at Veeva. “Veeva Vault
gives CLIOSS modern clinical applications to simplify collaboration with
sponsors and drive greater efficiency across its trials.”
Veeva Vault eTMF and Vault CTMS are part of the Veeva
Vault Clinical Operations Suite, which also includes Veeva
Vault Study Startup, to unify clinical operations on a single cloud
platform. Veeva’s suite of unified applications provides global
visibility into trial activities and streamlines end-to-end clinical
processes. For more information, visit veeva.com/eu/Clinical.
To learn more about how leading life sciences organizations are unifying
clinical operations, visit Veeva at booth #B08 at DIA
Europe 2019, in Vienna, Austria, February 5 - 7.
Additional Information
For more on Veeva Vault eTMF, visit: veeva.com/eu/products/vault-etmf/
For
more on Veeva Vault CTMS, visit: veeva.com/eu/products/vault-ctms/
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veeva_eu on Twitter: twitter.com/veeva_eu
Like
Veeva on Facebook: facebook.com/veevasystems
About CLIOSS
Based in Nerviano, Italy, CLIOSS, a NMS Group company, operates
internationally as a Contract Research Organization (CRO) for
biopharmaceutical companies, biotech and research institutes, IRCCS,
hospitals, and universities worldwide. Thanks to the diversified
capacity of the NMS Group companies and to their long-standing and broad
experience, CLIOSS’ services are flexible and range from comprehensive
drug development management to assistance with specific stages of the
study’s implementation or consultancy. For more information, visit clioss.com
and nervianoms.com.
Follow CLIOSS on LinkedIn.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 675 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,
visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2018. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190205005232/en/
Roger Villareal
Veeva Systems
+1-925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
Chiara Lattuada
CLIOSS
+39-333-8425690
chiara.lattuada@nmsgroup.it
Source: Veeva Systems